Previous close | 2.2200 |
Open | 2.2000 |
Bid | 2.1200 x 1000 |
Ask | 2.7000 x 1300 |
Day's range | 2.1350 - 2.2500 |
52-week range | 2.1350 - 8.9000 |
Volume | 126,594 |
Avg. volume | 163,606 |
Market cap | 39M |
Beta (3Y monthly) | 0.30 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Endologix (ELGX) delivered earnings and revenue surprises of 15.63% and 1.46%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Endologix (ELGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Endologix (ELGX) delivered earnings and revenue surprises of 53.75% and 0.41%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Endologix (ELGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
As of late, it has definitely been a great time to be an investor in Endologix, Inc. (ELGX).
Endologix, Inc. (NASDAQ:ELGX) shareholders should be happy to see the share price up 15% in the last month. But that...
Zacks.com featured highlights include: Avis, California Resources, Brinker, Endologix and Brookdale
In view of the ongoing uncertainties it is in the best interest of investors to seek guidance from brokers for designing a winning portfolio of stocks.
Endologix (ELGX) delivered earnings and revenue surprises of 28.21% and 4.19%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Endologix (ELGX) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Endologix, Inc.'s (NASDAQ:ELGX) released its most recent earnings update in December 2018, which suggested company earnings became less negative compared to the previous year's level - great news for investorsRead More...
Endologix (ELGX) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Endologix (ELGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
WellCare Health's (WCG) Q4 earnings gain from Meridian buyout and growth in membership.
Humana's (HUM) fourth-quarter earnings gain on the back of Medicare Advantage membership growth and operating efficiencies.
Centene's (CNC) Q4 earnings ride high on robust revenues, solid acquisitions and stronger Health Insurance Marketplace business.
The big shareholder groups in Endologix, Inc. (NASDAQ:ELGX) have power over the company. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. Read More...